rs1800693 — TNFRSF1A

TNFRSF1A Δ6 — The Genetic Reason Anti-TNF Drugs Fail in MS

The TNFRSF1A gene encodes TNF receptor 1 (TNFR1)¹¹ TNF receptor 1 (TNFR1)
the primary signaling receptor for tumor necrosis factor-alpha, expressed on nearly all nucleated cells, a central mediator of inflammation and immune defense. When TNF-alpha binds TNFR1, it can trigger apoptosis, pro-inflammatory gene activation, or cell survival depending on context. In the central nervous system, TNF signaling plays a particularly complex role: certain TNF signals are neuroprotective and promote myelin repair, while others drive inflammation. This duality explains one of the most important drug paradoxes in modern medicine: anti-TNF biologics like infliximab, adalimumab, and etanercept — transformative drugs for rheumatoid arthritis and Crohn's disease — consistently worsen multiple sclerosis. A splice-region variant in TNFRSF1A, rs1800693, now explains precisely why.

The Mechanism

rs1800693 sits at the 3′ end of exon 6, 10 nucleotides into the flanking intron, at a position that influences how the pre-mRNA is spliced. The risk allele (C on the plus strand) promotes skipping of exon 6²² The risk allele (C on the plus strand) promotes skipping of exon 6
Exon 6 encodes the transmembrane and cytoplasmic anchor domains of TNFR1; skipping it creates a truncated, secreted protein during mRNA processing. The resulting truncated protein — called TNFRSF1A Δ6, or Δ6-TNFR1 — retains the extracellular TNF-binding domain but lacks the transmembrane and intracellular signaling portions. Without an anchor to the cell membrane, Δ6-TNFR1 is secreted as a soluble, circulating decoy receptor³³ soluble, circulating decoy receptor
Δ6-TNFR1 binds TNF-alpha in the bloodstream and blocks it from engaging membrane-bound TNFR1, with weaker affinity than full-length TNFR1 but still functionally relevant that soaks up free TNF-alpha before it can activate inflammatory signaling.

The Δ6 isoform represents on average 27% of total TNFRSF1A transcript in CC homozygotes, making it a substantial contributor to TNFR1 biology. The key insight from Gregory et al. (Nature, 2012)⁴⁴ Gregory et al. (Nature, 2012)
TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis is that Δ6-TNFR1 does exactly what anti-TNF drugs do — it neutralizes TNF-alpha — but at a lower magnitude and with tissue-specific effects the pharmaceutical agents cannot replicate.

The Evidence

De Jager and colleagues⁵⁵ De Jager and colleagues
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nature Genetics 2009 first identified the TNFRSF1A locus in a GWAS meta-analysis of 2,624 MS cases and 7,220 controls, achieving combined p = 1.59×10⁻¹¹. The rs1800693 C allele showed an odds ratio of 1.2 — modest but highly significant due to its common frequency (~41% in Europeans). The locus contains two independent MS-associated variants: rs1800693 (common, OR 1.2) and the nearby coding variant rs4149584/R92Q (rare, 2% allele frequency, OR 1.6).

Replication across 11 European populations⁶⁶ Replication across 11 European populations
Genetic association of variants in CD6, TNFRSF1A and IRF8 to MS: a multicenter case-control study. PLoS ONE 2011 in 7,665 MS cases and 8,051 controls confirmed the association of rs1800693 (p = 4.19×10⁻⁷, OR = 1.12), cementing the locus as a true MS susceptibility signal.

The mechanistic breakthrough came with Gregory et al. Nature 2012⁷⁷ Gregory et al. Nature 2012
rs1800693 C allele generates Δ6-TNFR1, a soluble TNF antagonist explaining why anti-TNF drugs worsen MS: the C allele generates Δ6-TNFR1, which has nanomolar TNF-binding affinity and can neutralize TNF signaling in the CNS — the same mechanism exploited by pharmaceutical TNF inhibitors. Since pharmacological TNF blockade consistently worsens MS (multiple clinical trials were terminated early for this reason), and the rs1800693 C allele generates an endogenous TNF antagonist, this provides a compelling genetic explanation for why anti-TNF therapy is harmful in MS.

Clinical follow-up in 772 MS patients⁸⁸ Clinical follow-up in 772 MS patients
Clinical relevance and functional consequences of the TNFRSF1A MS locus. Neurology 2013 found that rs1800693(C) primarily affects disease onset rather than progression, and that C allele carriers show enhanced monocyte transcriptional responses to TNF-alpha including CXCL10 upregulation. A clinical study of 2,032 MS patients⁹⁹ clinical study of 2,032 MS patients
TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with MS. Neurology 2013 confirmed no severity effect of rs1800693 on disease course.

Practical Implications

The pharmacogenomic significance of this variant is profound. All five approved anti-TNF biologic agents — infliximab (Remicade), adalimumab (Humira), etanercept (Enbrel), golimumab (Simponi), and certolizumab (Cimzia) — carry warnings about new-onset or worsening demyelinating disease, and are absolutely contraindicated in patients with MS or demyelinating disorders. The rs1800693 locus provides the mechanistic explanation: blocking TNF-alpha in the CNS disrupts neuroprotective TNF signaling through TNFR2 and impairs myelin repair mechanisms that are distinct from the peripheral inflammatory effects where anti-TNF therapy is beneficial.

For patients with an autoimmune condition requiring biologic therapy, awareness of this variant helps contextualize the risk. If you develop an inflammatory condition like rheumatoid arthritis or Crohn's disease AND experience neurological symptoms suggestive of demyelination, anti-TNF therapy becomes contraindicated regardless of genotype. The genotype contextualizes the underlying susceptibility mechanism, not just drug risk in isolation.

Interactions

The TNFRSF1A locus harbors two independent MS susceptibility variants: rs1800693 (this entry, common, splice-region) and rs4149584 (R92Q, rare coding variant, OR = 1.6). These are not in strong linkage disequilibrium (r² = 0.041 in HapMap CEU) and confer independent risk. rs4149584/R92Q also causes TRAPS (TNF receptor-associated periodic syndrome)¹⁰¹⁰ TRAPS (TNF receptor-associated periodic syndrome)
an autoinflammatory disorder with recurrent fever, myalgia, abdominal pain, and conjunctivitis at low penetrance — a distinct phenotype from the MS susceptibility conferred by rs1800693.

In the broader TNF pathway, the related promoter variant rs1800629 (TNF-308 G>A in the TNF gene itself) drives elevated TNF-alpha production. These variants interact at a pathway level: high TNF production (rs1800629 A allele) combined with impaired TNF-TNFR1 signaling via the Δ6 decoy isoform (rs1800693 C allele) could perturb the fine-tuned balance of TNF signaling critical in the CNS. No formal compound analysis of these two variants in MS has been published, but the mechanistic logic supports compound monitoring if both risk alleles are present.